SOGROYA DIN 02539950
Status: Marketed
Holder: NOVO NORDISK CANADA INC
Available to quote
Health Canada record
| Active ingredient(s) | SOMAPACITAN 15 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | H01AC07 SOMAPACITAN |
|---|
| Original market date | 27-Nov-2023 |
|---|
| Current status date | 27-Nov-2023 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Novo Nordisk Canada Inc — licence 100175, currently licensed, last inspection rating C (2023-02-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SOMAPACITAN
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02539934 | SOGROYA | NOVO NORDISK CANADA INC | Solution | SOMAPACITAN 5 MG | Marketed |
| 02539942 | SOGROYA | NOVO NORDISK CANADA INC | Solution | SOMAPACITAN 10 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 31315 | 2023-07-26 | New Drug Submission (NDS) | |
Request a quote for SOGROYA
How to read a Canadian DIN record